drugset
drugset / Trial / NCT03001297

Phase 1, Single Dose Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of MEDI5884

NCT03001297 ↗

Phase 1 Completed 64 enrolled MedImmune LLC
RandomizedParallel-groupDouble-blindTreatment

Summary

A Phase 1, single dose study with 4 cohorts of ascending doses and an optional Japanese cohort designed to evaluate the safety, pharmacokinetics, and pharmacodynamics of MEDI5884 in healthy volunteers

Timeline

Start
2017-01-17
Primary completion
2018-08-10
Completion
2018-08-10

Drugs

EvaluationDrugModalityDoseRoute
Subject MEDI5884 Monoclonal antibody — Subcutaneous

Indications

No indication recorded.